Physician profile
Brian Bobb
NPI 1144280991
$7,773.45
in general payments reported to CMS, 2019-2025
21 companies · $5,805 in 2025
The $5,805 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $156 · 2021: $693 · 2022: $234 · 2023: $19.03 · 2024: $765 · 2025: $5,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,805 · Food and Beverage: $503 · Travel and Lodging: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,805.00 |
| Food and Beverage | $503.35 |
| Travel and Lodging | $280.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,571.57 | 2020-2025 | |
| Glaxosmithkline, LLC. | $222.65 | 2020-2022 | |
| Abbvie INC. | $185.70 | 2021-2024 | Vraylar |
| Novo Nordisk INC | $92.05 | 2021 | |
| Cmp Pharma, INC. | $83.79 | 2022 | |
| Lilly USA, LLC | $69.05 | 2019-2022 | |
| Abbott Laboratories | $68.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $65.37 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.13 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.05 | 2019-2021 | |
| Astellas Pharma US INC | $47.95 | 2021 | |
| Esperion Therapeutics, INC. | $45.21 | 2021 | |
| Amarin Pharma, INC. | $45.07 | 2021 | |
| Merck Sharp & Dohme LLC | $44.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $37.86 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $15.66 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.60 | 2020 | |
| Shire North American Group INC | $14.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.05 | 2022 | |
| Bausch Health US, LLC | $12.24 | 2022 | |
| Amgen INC. | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.